Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Health-related quality of life in recurrent platinum-sensitive ovarian cancer--results from the CALYPSO trial.
Brundage M, Gropp M, Mefti F, Mann K, Lund B, Gebski V, Wolfram G, Reed N, Pignata S, Ferrero A, Brown C, Eisenhauer E, Pujade-Lauraine E.
Ann Oncol. 2012 Jan 30. [Epub ahead of print]
Related citations
Prognostic significance of L1CAM in ovarian cancer and its role in constitutive NF-κB activation.
Bondong S, Kiefel H, Hielscher T, Zeimet AG, Zeillinger R, Pils D, Schuster E, Castillo-Tong DC, Cadron I, Vergote I, Braicu I, Sehouli J, Mahner S, Fogel M, Altevogt P.
Ann Oncol. 2012 Jan 6. [Epub ahead of print]
New drugs for ovarian cancer.
Bell-McGuinn K, Konner J, Tew W, Spriggs DR.
Ann Oncol. 2011 Dec;22 Suppl 8:viii77-viii82. Review. No abstract available.
Update on PARP1 inhibitors in ovarian cancer.
Sessa C.
Ann Oncol. 2011 Dec;22 Suppl 8:viii72-viii76.
The use of bevacizumab in the management of ovarian cancer: an argument for single-agent rather than combination therapy.
Markman M.
Ann Oncol. 2011 Dec;22 Suppl 8:viii69-viii71.
Antiangiogenic agents should be integrated into the standard treatment for patients with ovarian cancer.
Burger RA.
Ann Oncol. 2011 Dec;22 Suppl 8:viii65-viii68.
Designing early detection programs for ovarian cancer.
Urban N.
Ann Oncol. 2011 Dec;22 Suppl 8:viii6-viii18.
Molecular approaches to personalizing management of ovarian cancer.
Bast RC Jr.
Ann Oncol. 2011 Dec;22 Suppl 8:viii5-viii15. Review.
Optimal assessment of response in ovarian cancer.
Eisenhauer EA.
Ann Oncol. 2011 Dec;22 Suppl 8:viii49-viii51.
Follow-up with CA125 after primary therapy of advanced ovarian cancer has major implications for treatment outcome and trial performances and should not be routinely performed.
Rustin GJ.
Ann Oncol. 2011 Dec;22 Suppl 8:viii45-viii48.
Follow-up with CA125 after primary therapy of advanced ovarian cancer: in favor of continuing to prescribe CA125 during follow-up.
Pignata S, Cannella L, Leopardo D, Bruni GS, Facchini G, Pisano C.
Ann Oncol. 2011 Dec;22 Suppl 8:viii40-viii44.
Dose-dense therapy is of benefit in primary treatment of ovarian cancer: contra.
van der Burg ME, Boere IA, Berns PM.
Ann Oncol. 2011 Dec;22 Suppl 8:viii33-viii39.
Dose-dense therapy is of benefit in primary treatment of ovarian cancer? In favor.
Katsumata N.
Ann Oncol. 2011 Dec;22 Suppl 8:viii29-viii32. Review.
To predict or not to predict? The dilemma of predicting the risk of suboptimal cytoreduction in ovarian cancer.
Kang S, Park SY.
Ann Oncol. 2011 Dec;22 Suppl 8:viii23-viii28.
Quality control in ovarian cancer surgery.
Hacker NF.
Ann Oncol. 2011 Dec;22 Suppl 8:viii19-viii22. Review.
Clinical research in epithelial ovarian cancer and patients' outcome.
Rochon J, du Bois A.
Ann Oncol. 2011 Nov;22 Suppl 7:vii16-vii19.
Why do our patients get chemotherapy until the end of life?
Braga S.
Ann Oncol. 2011 Nov;22(11):2345-8. Epub 2011 Sep 13. No abstract available.
Palliative chemotherapy during the last month of life.
Näppä U, Lindqvist O, Rasmussen BH, Axelsson B.
Ann Oncol. 2011 Nov;22(11):2375-80. Epub 2011 Mar 14.
Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial.
Gladieff L, Ferrero A, De Rauglaudre G, Brown C, Vasey P, Reinthaller A, Pujade-Lauraine E, Reed N, Lorusso D, Siena S, Helland H, Elit L, Mahner S.
Ann Oncol. 2012 May;23(5):1185-9. Epub 2011 Oct 5.
Trabectedin plus pegylated liposomal doxorubicin in the treatment of patients with partially platinum-sensitive ovarian cancer: current evidence and future perspectives.
Sehouli J, Alfaro V, González-Martín A.
Ann Oncol. 2012 Mar;23(3):556-62. Epub 2011 Jul 6.
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on